These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36542991)

  • 1. Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation.
    Jin X; Ma X; Zhao D; Yang L; Ma N
    Transl Oncol; 2023 Feb; 28():101603. PubMed ID: 36542991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang J; Huang H; Chen R; Lin Y; Ling Q
    Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.
    Chao JS; Zhao SL; Ou-Yang SW; Qian YB; Liu AQ; Tang HM; Zhong L; Peng ZH; Xu JM; Sun HC
    World J Gastroenterol; 2019 Oct; 25(37):5630-5640. PubMed ID: 31602163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review.
    Jin X; Zhang K; Fang T; Zeng X; Yan X; Tang J; Liang Z; Xie L; Zhao D
    Front Oncol; 2022; 12():951303. PubMed ID: 36119543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.
    Anugwom CM; Leventhal TM; Debes JD
    Hepatoma Res; 2022; 8():. PubMed ID: 35693455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
    Ho CM; Chen HL; Hu RH; Lee PH
    Ther Adv Med Oncol; 2019; 11():1758835919843463. PubMed ID: 31065295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
    Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
    Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.
    Luo Y; Teng F; Fu H; Ding GS
    World J Gastrointest Oncol; 2022 Jan; 14(1):163-180. PubMed ID: 35116109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma.
    Liang J; Bai Y; Ha FS; Luo Y; Deng HT; Gao YT
    World J Gastrointest Oncol; 2023 Jan; 15(1):1-18. PubMed ID: 36684055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for hepatocellular carcinoma: long-term results suggest excellent outcomes.
    Doyle MB; Vachharajani N; Maynard E; Shenoy S; Anderson C; Wellen JR; Lowell JA; Chapman WC
    J Am Coll Surg; 2012 Jul; 215(1):19-28; discussion 28-30. PubMed ID: 22608403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
    Yan J; Tan C; Gu F; Jiang J; Xu M; Huang X; Dai Z; Wang Z; Fan J; Zhou J
    Liver Transpl; 2013 May; 19(5):507-20. PubMed ID: 23408515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation.
    Ng KT; Lo CM; Wong N; Li CX; Qi X; Liu XB; Geng W; Yeung OW; Ma YY; Chan SC; Man K
    Oncotarget; 2016 Apr; 7(15):19824-39. PubMed ID: 26918346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.
    Yang Z; Wang S; Tian XY; Xie QF; Zhuang L; Li QY; Chen CZ; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):365-370. PubMed ID: 32553774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
    Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
    Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insight and judgment on recurrence of hepatocellular carcinoma after liver transplantation].
    Zheng H; Zhang HM; Zheng WP
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):88-92. PubMed ID: 29804372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.